Contents 2 min read
Claim and source comparison
Ginkgo biloba: dementia prevention, cognitive symptoms and safety.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human randomized controlled trial
The GEM trial randomized 3069 people aged 75 or older to 120 mg of leaf extract twice daily or placebo. The extract did not reduce new dementia cases over a median follow-up of 6.1 years.
The trial tracked new diagnoses in older adults who did not have dementia. It did not measure treatment of existing dementia symptoms.
Source 2 · Abstract read
Systematic review / meta-analysis
The 2026 Cochrane review found probably little to no difference in cognition, overall clinical status or daily function at 6 months in mild cognitive impairment. In dementia, these measures may improve somewhat, with low-certainty evidence.
Dementia trials produced markedly different results. Few reported follow-up beyond 6 months.
Source 7 · Abstract read
Official safety summary
NIH NCCIH warns that ginkgo may raise bleeding risk in people taking anticoagulants such as warfarin. Dizziness, digestive symptoms and headache have been reported with leaf extracts. Fresh seeds are toxic.
This summary does not quantify bleeding risk for each product and medicine combination.
Source 6 · Official summary read
Correction · 2026-11-11. The prevention and symptom findings were distinguished. The general dose range and definitive clinical mechanism claims were removed.
What is Ginkgo Biloba?
Ginkgo biloba is the world's oldest tree species, known as a "living fossil" and appearing approximately 250 million years ago. The leaves of this plant, which has been used in traditional medicine in China for thousands of years, are also the focus of modern neuroscience research.
Ginkgo biloba used for nootropic purposes is not the raw leaf, standardized leaf extract. The most commonly researched form EGb 761 It is standardized to contain 24% flavonoid glycosides and 6% terpenlactone.
Active Compounds and Mechanism of Action
Ginkgo leaf extract contains flavonoids and terpene lactones. Mechanisms proposed for these constituents do not establish cognitive benefit or increased cerebral blood flow in humans.
Clinical Evidence
The GEM trial randomized 3069 people aged 75 or older to 120 mg of leaf extract twice daily or placebo. The extract did not reduce new dementia cases over a median follow-up of 6.1 years.
The 2026 Cochrane review found probably little to no difference in cognition, overall clinical status or daily function at 6 months in mild cognitive impairment. In dementia, these measures may improve somewhat, with low-certainty evidence.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
NIH NCCIH warns that ginkgo may raise bleeding risk in people taking anticoagulants such as warfarin. Dizziness, digestive symptoms and headache have been reported with leaf extracts. Fresh seeds are toxic.
NCCIH cautions that use during pregnancy may be unsafe. Little is known about safety during breastfeeding.
Sources
- Le Bars PL, et al. (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA, 278(16), 1327–1332. PubMed · PMID 9343463
- DeKosky ST, et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300(19), 2253–2262. PubMed · PMID 19017911
- Weinmann S, et al. (2010). Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics, 10, 14. PubMed · PMID 20236541
- Brondino N, et al. (2013). A systematic review and meta-analysis of Ginkgo biloba in neuropsychiatric disorders: from ancient tradition to modern-day medicine. Evidence-Based Complementary and Alternative Medicine, 2013, 915691. PubMed · PMID 23781271
- Tan MS, et al. (2015). Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. Journal of Alzheimer's Disease, 43(2), 589–603. PubMed · PMID 25114079
- NIH NCCIH. Ginkgo: Usefulness and Safety. https://www.nccih.nih.gov/health/ginkgo NIH NCCIH
- Wieland LS, et al. (2026). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, Issue 2, CD013661. PubMed · PMID 41641880
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Findings on ginkgo for dementia symptoms are mixed. Prevention of dementia, cognitive enhancement in healthy people or relief of tinnitus has not been established; bleeding interactions require caution.
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
NIH NCCIH warns that ginkgo may raise bleeding risk in people taking anticoagulants such as warfarin. Dizziness, digestive symptoms and headache have been reported with leaf extracts. Fresh seeds are toxic.
No established timeframe
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.